Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811 and SHR-A1921 combined with adebrelimab in HER2-negative advanced breast cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
131 participants in 2 patient groups
Loading...
Central trial contact
Yang Ke
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal